DGAP-News

Epigenomics AG: Epigenomics Provides Corporate Update - Seite 2

on the information provided and on the promising results of BioChain's
clinical trial announced in April 2014, the company expects an approval
decision in the foreseeable future.

Lastly, Epigenomics expects that it will make use of available financing
options before the end of the year. , Epigenomics is seeking to extend its
cash reach to secure the necessary funds for the execution of important
next steps and completion of the above mentioned milestones.

"We will keep the markets updated on future developments and announce major
steps regarding progress in the ADMIT trial and our ongoing market
applications in the US and China", stated Thomas Taapken, CEO of
Epigenomics. "After very busy summer months preparing for the ADMIT trial,
we are now ready to embark on the final steps of the approval for Epi
proColon(R) in the US and China. We remain optimistic about the prospects
of the Company and thank our shareholders for their ongoing support."

- End -

Contact Epigenomics AG

Antje Zeise, Manager IR | PR
Epigenomics AG
Geneststraße 5
10829 Berlin
Tel [phone]
[e-mail]
www.epigenomics.com

For U.S. press inquiries:
Epigenomics, Inc.
20271 Goldenrod Lane, Suite 2027
Germantown, Maryland 20876
[e-mail]


About Epigenomics

Epigenomics (www.epigenomics.com) is a molecular diagnostics company
developing and commercializing a pipeline of proprietary products for
cancer. The Company's products enable doctors to diagnose cancer earlier
and more accurately, leading to improved outcomes for patients.
Epigenomics' lead product, Epi proColon(R), is a blood-based test for the
early detection of colorectal cancer, which is currently marketed in Europe
and is under regulatory review by the FDA for the U.S.A. and the Chinese
Food and Drug Administration for China. Additionally, the Company markets
its tissue assay for use in lung cancer diagnosis, Epi proLung(R), in
Europe. The Company's technology and products have been validated through
multiple partnerships with leading global diagnostic companies and testing
laboratories. Epigenomics is an international company with operations in
Europe and the U.S.A.

Epigenomics legal disclaimer

This communication expressly or implicitly contains certain forward-looking
statements concerning Epigenomics AG and its business. Such statements
involve certain known and unknown risks, uncertainties and other factors
which could cause the actual results, financial condition, performance or
achievements of Epigenomics AG to be materially different from any future
results, performance or achievements expressed or implied by such